
CervoMed Inc (CRVO) Stock Forecast & Price Target
CervoMed Inc (CRVO) Analyst Ratings
Bulls say
CervoMed is a promising clinical-stage biotechnology company with a strong potential for success due to their product candidate, Neflamapimod, which has shown promise in treating age-related neurologic disorders by improving synaptic dysfunction. The company's financials and key data metrics, including a 12-month target price of $25 per share and a $410M total enterprise value, further support this positive outlook, with risks including delays in clinical trials and regulatory approvals. Additionally, recent MRI data and improved functional connectivity further strengthen the potential for success and likely market uptake of neflamapimod.
Bears say
CervoMed is facing significant risks in its path towards Phase 3 development and potential commercialization of neflamapimod for DLB. These include uncertainties in clinical trials and regulatory approval, lack of partnerships and potential financing struggles, and competition in the market for neurologic disorder treatments. Additionally, the company still needs to clarify the benefit of neflamapimod in patients without AD co-pathology, a crucial factor in its success as a treatment.
This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.
CervoMed Inc (CRVO) Analyst Forecast & Price Prediction
Start investing in CervoMed Inc (CRVO)
Order type
Buy in
Order amount
Est. shares
0 shares